Senate Report On DOD Funding
On September 15, the Senate Committee on Appropriations approved their FY12 report by a vote of 30-0. Included in the report was their recommendations for the Department of Defense Research Programs. […]
Genetics & Calcium Might Increase Risk for Prostate Cancer In the African-American Men
A study by at Wake Forest Baptist Medical Center in Winston-Salem N.C., Keck School of Medicine at the University of Southern California (USC) and the Cancer Prevention Institute of California suggests that a high intake of calcium causes prostate cancer among African-American men who are genetically good absorbers of the mineral. According to Gary G. [...]
Morbidity and Treatment Regret in Men with Advanced Prostate Cancer
The question of today’s post is do men with advanced prostate cancer develop treatment regrets concurrent to their development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation)? To answer this question researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry [...]
Cabozantinib, Promising, Still Controversial For the Treatment of Bone Mets in Prostate Cancer
Cabozantinib (cabo), has many of us prostate cancer survivor, educators and researchers simply scratching their heads. In trials, Cabozantinib demonstrated what some people have characterized as mind boggling activity against bone metastases. In trials the drug led to partial or complete resolution of bone scans in a substantial portion of patients with cancer, including prostate, [...]
Genome-wide Association Study Identifies a Genetic Variant Associated with Risk for More Aggressive Prostate Cancer
It is estimated that in the United States 200,000 men will be diagnosed with prostate cancer each year with approximately 20% to 30% having clinically aggressive prostate cancer. When diagnosed the standard is to consider factors such as Gleason score and tumor stage to assess a man’s prognosis, however there are no biomarkers to identify [...]